Skip to main content
. Author manuscript; available in PMC: 2009 Mar 1.
Published in final edited form as: Immunity. 2008 Aug 14;29(3):391–403. doi: 10.1016/j.immuni.2008.07.011

Figure 5. Transgenic Expression of PLZF converts CD4 thymocytes into effector cells.

Figure 5

(A) Left, CD4/CD8 FACS dot plots of lymphocytes from various organs of CD4 promoter-PLZF transgenic and wild type littermates (CD1d-αGC Tetramer-positive cells are gated out). Right, CD44/CD62L expression by CD4 cells of indicated organs gated as shown on the left panels. Data representative of two independent transgenic lines 1797 and 1960.

(B) PLZF transgenic CD4 cells in competitive chimeras. Wild-type (CD45.1+) and PLZF Tg (CD45.2+, line 1797) bone marrow cells were mixed 1:1 to reconstitute lethally irradiated wild type recipients. Thymus and spleen cells were stained as indicated (left panels) to gate CD4 and CD8 T cells for analysis of CD44 and CD45.1 (middle and right panels) Chimeras were analyzed 6.5 weeks after transfer. Data are representative of four individual chimeras.

(C) Cell cycle analysis 3 hours after in vivo injection of 100µg of 5-ethynyl-2'-deoxyuridine (EdU) into mixed bone marrow chimeras. Edu incorporation was detected by intracellular flow cytometry for DP (left panels) and CD4 single positive (right panels) thymocytes of wt (top panels) and PLZF-Tg (bottom panels) origin, as indicated. Similar values were obtained for splenic CD4 cells (not shown). Data are representative of three individual chimeras and two independent experiments.

(D) Frequency and tissue distribution of NKT cells in PLZF-transgenic mice. Data are from the same mixed bone marrow chimeras as in Fig. 5B and represent percentages of NKT cells among wild-type (CD45.1+) and PLZF Tg (CD45.2+) lymphocytes.